CCP
TXMD icon

Clough Capital Partners’s TherapeuticsMD TXMD Stock Holding History

Clough Capital Partners’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,331
Closed -$2.12M – 163
2017
Q1 		$2.12M Hold
7,331
– – 0.13% 91
2016
Q4 		$2.12M Sell
7,331
-159
-2% -$49.3K 0.14% 106
2016
Q3 		$2.55M Sell
7,490
-600
-7% -$219K 0.13% 120
2016
Q2 		$3.44M Sell
8,090
-228
-3% -$94K 0.18% 118
2016
Q1 		$2.66M Buy
8,318
+54
+0.7% +$18.4K 0.13% 128
2015
Q4 		$4.29M Sell
8,264
-2,844
-26% -$1.05M 0.2% 110
2015
Q3 		$3.25M Sell
11,108
-662
-6% -$235K 0.14% 114
2015
Q2 		$4.63M Sell
11,770
-504
-4% -$178K 0.18% 112
2015
Q1 		$3.71M Sell
12,274
-1,394
-10% -$340K 0.12% 142
2014
Q4 		$3.04M Sell
13,668
-948
-6% -$196K 0.11% 135
2014
Q3 		$3.39M Buy
14,616
+1,229
+9% +$310K 0.13% 129
2014
Q2 		$2.96M Buy
13,387
+5,817
+77% +$1.29M 0.09% 147
2014
Q1 		$2.39M Buy
+7,570
New +$2.41M 0.07% 153

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Clough Capital Partners's TXMD Position: Q2 2017 in Review

Clough Capital Partners sold out of TherapeuticsMD (TXMD) in Q2 2017, closing a stake of 7,331 shares — an estimated $2.12M sold.

Clough Capital Partners first reported a position in TXMD in Q1 2014 and held it in 13 quarters. The position peaked at $4.63M in Q2 2015. 117 funds tracked by Wall St. Rank hold TXMD as of Q2 2017.

  • Clough Capital Partners reported no remaining TherapeuticsMD position as of Q2 2017 after selling out during the quarter.
  • Clough Capital Partners sold 7,331 TherapeuticsMD shares in Q2 2017, an estimated $2.12M.
  • Clough Capital Partners first reported a position in TherapeuticsMD in Q1 2014 and held it in 13 quarters.
  • Clough Capital Partners's TherapeuticsMD position peaked at $4.63M in Q2 2015.
  • 117 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2017.

Based on Clough Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.